RE:RE:RE:RE:British Columbia Securities Commission!! ROSIE2023 asked why the Bioasis IP is taking so long to make it to market if it works.
It's possible that there are deals that have been held back due to a de facto standstill for the last 12 to 18 months. I have already written it all out a number of times and I won't bore you with it again here.
A player like Ladenburg Thalmann (LT) could very easily tell its client(s) that trying to set up a strategic plan and executing it are almost impossible if either or both of the companies are moving targets. If Bioasis executed business deals at any time beginning perhaps as early as mid 2021, then that would have caused continuous reassessments of Bioasis's value. Good business deals do three things. They bring in immediate funding to pay operating costs and loans. They cause the share price to go up because of the immediate funding. And they signal that more deals are likely coming, further supporting the share price.
My question is whether LT took so long to bring a deal to the table, deliberately or not, that Bioasis, unable to do business deals, ran out of money. This then brought Lind back in to "support" Bioasis until the "merger" got done. That was checkmate. Lind obtained a call on Bioasis assets.
If that was LT's plan, setting up the potential default, then the remaining major question is whether Dr. Deborah Rathjen participated in the plan or whether she was outwitted. I am really suspicious of how xB3 was downplayed and Cresence was brought in to replace it in promotional literature. It's one thing to avoid deals because of a standstill but it's something entirely different to under-promote xB3 and Bioasis's value.
Either way, Bioasis is facing an existential threat because of the plan put together by LT, the placee, Lind, Bioasis and Midatech. So if Bioasis would be damaged beyond repair by either success or failure of the "merger", then why is Dr. Deborah Rathjen still a part of Bioasis?
DrDR continues to express that she is disappointed that the Midatech deal failed.
Did Dr. Deborah Rathjen prevent business deals from being done in order to get the "merger" done? Was there even one deal that could have been done that would have allowed the whole "merger" thing to go away? Was there a deal with Ellipses? Why did Janssen/J&J extend its option instead of exercising it?
Shareholders are tired of having to guess at the answers.
I fully support the forces at work behind the scenes who are discussing ways to fix this flipping mess.
jd